The British Home Secretary has announced that specialized clinicians will be allowed to legally prescribe cannabis by the autumn. The announcement was the result of a two-part review the Secretary commissioned on June 19.
According to the Gov.UK website, “The Advisory Council on the Misuse of Drugs (ACMD) carried out the second part of the review, considering the appropriate schedule for cannabis-derived medicinal products, based on the balance of harms and public health requirements. The ACMD recommended that such products meeting a clear definition of what constitutes a cannabis-derived medicinal product should be placed in Schedule 2 of the Misuse of Drugs Regulations 2001.”
This action is rooted in two developments in the U.K. Firstly, there has been intense pressure from the parents of children with intractable epilepsy. These parents have been routinely traveling to the U.S. to see if their child responds to cannabis-derived preparations like Charlotte’s Web. Secondly, the British based company, GW Pharmaceuticals, recently received U.S. FDA approval to market their anti-epilepsy drug, epidiolex. The company is awaiting action by the DEA to rescheduled appropriate cannabinoids so the new cannabis-derived preparation can be prescribed. The ACMD, according to the news release, “recommended that such products meeting a clear definition of what constitutes a cannabis-derived medicinal product should be placed in Schedule 2 of the Misuse of Drugs Regulations 2001.”
Other forms of cannabis will be kept under strict controls.
This move by U.K. officials will likely be copied by the DEA.
Read more here: